GlassScriptPhysician profile
Hieu T Vu
NPI 1932161346
$9,091.71
in general payments reported to CMS, 2019-2025
48 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $707 · 2020: $995 · 2021: $1,343 · 2022: $1,192 · 2023: $1,597 · 2024: $1,698 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,855.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,159.80 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,010.53 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $895.77 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $873.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.75 | 2019-2025 | Jardiance, Spiriva Respimat |
| Novo Nordisk INC | $532.28 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $309.74 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $286.04 | 2019-2022 | |
| Abbott Laboratories | $280.86 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $274.36 | 2019-2021 | |
| Exact Sciences Corporation | $239.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $209.38 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $183.15 | 2022-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $182.18 | 2023-2024 | Quviviq |
| Amgen INC. | $174.88 | 2021-2025 | Repatha, Otezla, Repatha |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hieu Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.